Cas9 Stable Cell Line - MCF-7

Over 70% of breast tumors express the nuclear receptor (NR) estrogen receptor-α (ERα) and rely heavily on its signaling for tumor growth. The researchers used genome-scale CRISPR-Cas9 screens in MCF-7 breast cancer cells under SI-12 pharmacological pressure to find gene targets that enhance BC cell cytotoxicity. A parallel screen utilizing the ER inhibitor fulvestrant revealed insights into SRC-3 and ERα inhibitory actions. Validating findings from MCF-7 screenings in different cancer cell lines increased our understanding of SRC-3's role in carcinogenesis beyond breast cancer.

Figure 1. In MCF-7 cells, the researchers performed a pooled CRISPR/Cas9 screening with the genome-wide single vector library GeCKOv2. Cells were treated to greater pharmacological pressure using SRC-3 inhibitors SI-12 or ICI to find genetic vulnerabilities for medication combinations. gDNA was obtained at three time periods, amplified by PCR in bar-coded areas, and evaluated by NGS. (Gilad Y, et al., 2021)

Unlock the potential of genome-scale CRISPR-Cas9 screens with Creative Biogene's Cas9 Stable Cell Line-MCF-7. Engineered for stability and efficiency, this cell line ensures reliable Cas9 expression, empowering precise gene editing under pharmacological pressures like SI-12. Conduct parallel screens with confidence using inhibitors such as fulvestrant to explore SRC-3 and ERα inhibition synergies. Validate hits across diverse cancer cell lines effortlessly, gaining deeper insights into cancer biology and therapeutic targets.